Ozagrel free acid
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330220

CAS#: 82571-53-7 (free base)

Description: Ozagrel, also known as KCT-0809 and Cataclot, is a thromboxane A2 synthase inhibitor used to treat cerebrovascular diseases.


Price and Availability

Size Price Shipping out time Quantity
1g USD 250 2 Weeks
2g USD 450 2 Weeks
5g USD 750 2 Weeks
10g USD 1250 2 Weeks
25g USD 2450 2 Weeks
50g USD 4650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-22. Prices are subject to change without notice.

Ozagrel free acid, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 330220
Name: Ozagrel free acid
CAS#: 82571-53-7 (free base)
Chemical Formula: C13H12N2O2
Exact Mass: 228.0899
Molecular Weight: 228.251
Elemental Analysis: C, 68.41; H, 5.30; N, 12.27; O, 14.02


Related CAS #: 189224-26-8 (sodium)   82571-53-7 (free base)  

Synonym: Ozagrel; KCT-0809; KCT 0809; KCT0809; Cataclot; Xanbo; Ozagrel free acid

IUPAC/Chemical Name: (E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylic acid

InChi Key: SHZKQBHERIJWAO-AATRIKPKSA-N

InChi Code: InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

SMILES Code: O=C(/C=C/C1=CC=C(C=C1)CN2C=CN=C2)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Park SI, Park SK, Jang KS, Han YM, Kim CH, Oh SJ. Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. Brain Res. 2015 Mar 2;1599:85-92. doi: 10.1016/j.brainres.2014.12.051. Epub 2014 Dec 31. PubMed PMID: 25555371.

2: Wada T, Yasunaga H, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N. Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis. J Stroke Cerebrovasc Dis. 2016 Aug 23. pii: S1052-3057(16)30261-0. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.044. [Epub ahead of print] PubMed PMID: 27567296.

3: Tange M, Yoshida M, Hazekawa M, Haraguchi T, Nakai Y, Uchida T. Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product. Chem Pharm Bull (Tokyo). 2013;61(5):567-71. Epub 2013 Mar 1. PubMed PMID: 23449252.

4: Zhang J, Yang J, Chang X, Zhang C, Zhou H, Liu M. Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurol Res. 2012 May;34(4):346-53. doi: 10.1179/1743132812Y.0000000022. PubMed PMID: 22643078.

5: Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. PLoS One. 2014 Feb 13;9(2):e88440. doi: 10.1371/journal.pone.0088440. eCollection 2014. PubMed PMID: 24551100; PubMed Central PMCID: PMC3923787.

6: Xu SH, Yin MS, Liu B, Chen ML, He GW, Zhou PP, Cui YJ, Yang D, Wu YL. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion. Hum Exp Toxicol. 2016 Jul 6. pii: 0960327116657401. [Epub ahead of print] PubMed PMID: 27387348.

7: Wu H, Yu W, Huang L, Wang J, Tang X, Yang W, Liu Y, Yu H, Zhu D. Effect of sodium ozagrel on the activity of rat CYP2D6. Eur J Pharmacol. 2007 Nov 14;573(1-3):55-9. Epub 2007 Jul 4. PubMed PMID: 17651725.

8: Shinohara Y, Inoue S. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. J Stroke Cerebrovasc Dis. 2013 Jul;22(5):668-74. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.002. Epub 2012 May 22. PubMed PMID: 22622391.

9: Yao HX, Huang L, Wu CM, Lin LE, Huang ZQ, Wu JF, Wang SW, Chen WT, Tang RM. [Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1360-2. Chinese. PubMed PMID: 19840484.

10: Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009;27(5):485-92. doi: 10.1159/000210190. Epub 2009 Mar 26. PubMed PMID: 19321945.